“From academic research centers to intensive care units (ICUs) to scientific journals to government agencies, scientists fighting the pandemic say they are hitting a wall, 15 months after the first report of a cluster of cases introduced the virus “

Can we work faster to make vaccines? How can we get vaccines distributed across the world? What are the ethical challenges of vaccine distribution? All these questions need to be considered for what it takes to vaccinate the world against COVID-19.

Surrogate decision-making process for incarcerated persons lack state/national standards. “Failure to address this inadequacy with well thought-out practical protocols further perpetuates the known disparities in care suffered by this group.”

What does the future of human genomics and equity look like? “This special issue of Nature examines how far the human genome sequence has taken us, and how far we have to go.”

What drives vaccine hesitancy among healthcare workers? “The hesitancy is less outright rejection than cautious skepticism. It’s driven by suspicions about the evidence supporting the new vaccines and about the motives of those endorsing them.”

“The question then is this: Is it appropriate to continue to keep children out of school until teachers or reticent politicians feel they have a degree of certainty about risk that may not arise for a long time, if ever?” What do we need to consider?

A big component of vaccine distribution has been utilizing ethics to determine vaccine prioritization. Issac Chotiner of The New Yorker speaks with immunologist Barry Bloom to discuss what goes into making decisions on vaccine distribution.

Why has vaccine distribution fallen into disarray across the United States? Lack of funding and coordination between state and local governments has left citizens confused about their vaccination opportunities. What will come in year 2 of COVID-19?

Recent data has shown COVID-19 numbers are trending in the wrong directions for our populations at risk. With the vaccine soon to be rolled out, what needs to be considered in distribution as we look at the effects of COVID-19 on elderly populations?

AstraZeneca recently disclosed a key mistake in their vaccine trials. How will this impact the trust and reliability of their results? What ethics needs to be considered regarding this mistake? Can these results now hold up with further testing?